Institut Curie and the Institut de Recherche Pierre Fabre (IRPF) will collaborate on new therapeutic strategies to advance cancer treatment for patients.
The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models.
Director of the Institut Curie Center of Cancer immunotherapy and U932 Institut Curie / INSERM / UPMC research unit, Sebastian Amigorena explains: “We will work to better understand the immunological responses to tumours, and to learn how to use the immune system to fight cancer.
“Research projects will range from analysis of the most fundamental aspects of intracellular transport in cells of the immune system to functional aspects of immune responses to tumours in animal models and to clinical immunotherapy in cancer patients.”
Head of Pierre Fabre oncology innovation unit Eric Chetaille says: “Pierre Fabre’s know-how in oncology is based on more than 30 years of experience. This strategic partnership is in line with our commitment to deliver transformative therapies to patients afflicted with cancer. It will combine the accumulated knowledge in immuno-oncology gathered by oncologists and biologists at the Institut Curie with the capabilities of Pierre Fabre and the expertise of our researchers and product development teams.
“It is a great opportunity to strengthen our research capabilities in cancer immunotherapy and to ultimately open up promising prospects for the discovery of new cancer treatments”
Sebastian Amigorena and Claire Hirvoz teams work to better understand the tumour immunerelated microenvironment and to learn how to use the immune system to fight cancer. Their projects range from basic immunology in healthy individuals to more applied studies of immune response in the context of tumour using animal models or human biological samples from cancer patients.
Head of the Institut Curie Technology Transfer and Industrial Partnerships Office and director of Institut Carnot Curie Cancer Amaury Martin says: “This new partnership in the field of immuno-oncology with one of the top French company investing in research and development (R&D) illustrates the current dynamism of Tech Transfer at Institut Curie.
“Based on the expertise of the teams involved at Pierre Fabre and Institut Curie, the objective will be to develop new immunotherapies to bring innovative therapeutic solutions to the clinics”
Under the terms of this agreement, Institut Curie and the IRPF will collaborate on new therapeutic strategies to improve cancer treatment for patients. Both parties will interact closely to dissect the biology of novel therapeutically actionable targets and evaluate the impact of novel pharmacological approaches leveraging the Institut Curie’s biological models.